论文部分内容阅读
目的:探讨子宫内膜癌组织中原癌基因c-Ets-1的表达及其与子宫内膜癌的临床分期、病理分级、分型及预后关系。方法:采用免疫组化方法检测c-Ets-1蛋白在67份子宫内膜癌组织及34份正常子宫内膜组织中的表达。采用荧光原位杂交方法对其中12份子宫内膜癌标本及10份正常内膜组织中的c-Ets-1mRNA进行检测。结果:免疫组化结果显示c-Ets-1蛋白在子宫内膜癌组织中阳性表达率为86.5%,临床分期Ⅰ期、病理分级高分化、无肌层浸润及无复发的子宫内膜癌组织中c-Ets-1蛋白含量及阳性表达率明显低于临床分期Ⅱ、Ⅲ期、低分化、肌层浸润大于1/2及有复发的组织标本(P<0.05);而在正常子宫内膜中,仅呈阴性及少量呈弱阳性的改变。荧光原位杂交技术检测结果与免疫组织化学表达相符,在子宫内膜癌中阳性表达率为90.4%,而正常子宫内膜组织中,仅有少量呈阳性。结论:与正常对照相比,c-Ets-1有肿瘤特异性,其表达与子宫内膜癌的临床分期、病理分级及分型、转移及临床预后相关。
Objective: To investigate the expression of proto-oncogene c-Ets-1 in endometrial carcinoma and its relationship with clinical stage, pathological grade, classification and prognosis of endometrial carcinoma. Methods: The expression of c-Ets-1 protein in 67 endometrial carcinomas and 34 normal endometrial tissues was detected by immunohistochemistry. Fluorescence in situ hybridization was used to detect c-Ets-1 mRNA in 12 specimens of endometrial carcinoma and 10 specimens of normal endometrium. Results: Immunohistochemistry showed that the positive rate of c-Ets-1 protein in endometrial carcinoma was 86.5%. The clinical stage Ⅰ, the histological grade of well-differentiated, non-myometrial invasion and non-recurrence of endometrial carcinoma The content of c-Ets-1 protein and the positive expression rate were significantly lower than those in clinical stages Ⅱ and Ⅲ, with poorly differentiated and myometrial invasion more than 1/2 and recurrence (P <0.05), while in normal endometrium , Only negative and a small amount of weakly positive changes. Fluorescence in situ hybridization test results consistent with immunohistochemical expression in the endometrial cancer, the positive expression rate of 90.4%, while normal endometrial tissue, only a small amount of positive. Conclusion: Compared with normal control, c-Ets-1 has tumor specificity. The expression of c-Ets-1 is correlated with the clinical stage, pathological grade, classification, metastasis and clinical prognosis of endometrial carcinoma.